South Korea’s Biopharma Exports Reach Record $6.6 Billion Through September
South Korean biopharmaceutical exports rose 15.8 percent from a year earlier to a record $6.6 billion in the first nine months of 2026, driven by strong European demand for contract manufacturing services and biosimilars.
South Korea’s biopharmaceutical exports reached a record $6.6 billion in the first nine months of 2026, underscoring the sector’s growing contribution to the country’s pharmaceutical trade.
Shipments between January and September increased 15.8 percent from the same period a year earlier, according to data released Thursday by the Ministry of Food and Drug Safety. Biopharmaceutical products accounted for about 73 percent of South Korea’s total pharmaceutical exports, which stood at $9 billion during the period.
The momentum remained strong in the third quarter. Biopharmaceutical exports rose 15.6 percent year on year to $2.07 billion between July and September. The figures indicate that overseas demand continued to expand even as Korean exporters navigated uncertain global trading conditions.
The United States was the largest destination for South Korean biopharmaceutical shipments in the first nine months, receiving $1.07 billion worth of products. That represented 16.3 percent of the sector’s total exports. Switzerland ranked second with $1.01 billion, followed by Hungary at $920 million.
Europe was a particularly important source of growth. Seven of South Korea’s 10 largest export destinations were in the region. The ministry attributed the performance in part to solid demand for contract development and manufacturing organization services and for biosimilar medicines.
Contract development and manufacturing organizations provide services ranging from drug development support to large-scale commercial production for pharmaceutical companies. Biosimilars are highly similar versions of approved biological medicines. Both areas have become important parts of South Korea’s life-sciences export base.
The record result highlights the increasingly international reach of the country’s biopharmaceutical industry. It also shows how services and specialized medicines are shaping the composition of pharmaceutical exports, with biopharmaceutical products now making up nearly three-quarters of the total.
The geographic breakdown points to a broad mix of demand across the United States and Europe rather than reliance on a single market. At the same time, the concentration of seven leading destinations in Europe makes conditions in that region especially significant for the sector’s export outlook.
With nine-month shipments already at a record level, the final quarter will determine the full-year total. The latest data provide a strong base, supported by double-digit annual growth and demand for Korean manufacturing capabilities and biosimilar products.